Track habits, symptoms, nutrition, hydration, and personal notes to better understand how your routine is going over time
Presented for research literature review only Li R et al
Does Ipamorelin cause stomach issues
This finding challenges the assumption that targeting oxidative stress alone is sufficient to ameliorate ASD-like phenotypes, particularly when interventions are applied after critical neurodevelopmental windows
Mounjaro (Tirzepatide) Dual action: targets both GLP-1 and GIP receptors Strong appetite suppression & improved blood sugar control Clinical trials show average body weight loss up to 22.5% over 72 weeks Wegovy (Semaglutide) Targets GLP-1 receptors only Licensed in the UK for obesity and cardiovascular protection STEP trials show 1521% body weight loss A new 7.2mg dose is expected in late 2025, with results potentially matching Mounjaro Both treatments are once-weekly injections, prescribed alongside healthy diet and lifestyle changes
Stacking, such as combining BPC-157 with TB-500 for overlapping tendon and systemic repair goals, is a common practice among people pursuing compounded healing outcomes